Clean Harbors heads into its May 6 Q1 earnings release on a wave of analyst upgrades that the stock has largely caught up to.
The most telling move came from Citigroup, which upgraded the shares to Buy and lifted its target to $346 on April 8 — the most aggressive re-rating among a cluster of firms that also raised targets in mid-April. Truist raised its target to $325, and Baird pushed to $350, both maintaining positive ratings. Goldman Sachs lifted to $306 while keeping a Neutral stance, signalling the consensus has drifted higher but is not unanimous. The consensus mean target of $318 now sits only modestly above the current price of $311.43 — a gap of just 2.1% — meaning most of the re-rating is already in the share price. The stock is up 8.6% over the past month and has gained roughly 33% year-to-date, leaving bulls to argue the story still has legs and bears to ask how much further the earnings narrative can stretch.
The bull case centres on margin expansion, disciplined capital allocation, and potential new growth vectors — PFAS remediation and the new high-temperature incinerator in Kimball, Nebraska being the most cited. The bear case is not really negative on the business; it reads more like a valuation caution, with the company trading at a PE of 36 and an EV/EBITDA of around 14.7x that has risen over the past month. Forward EPS momentum is robust — the 12-month forward estimate is up sharply year-on-year, ranking in the 88th percentile — but that strength is already well-reflected in the multiple. The ORTEX analyst recommendation divergence factor ranks in the 94th percentile, suggesting the Street is more positively skewed versus the broader universe than it has been in some time.
Positioning in the lending market tells a quiet story. Short interest is at just 1.46% of the free float, down more than 11% on the week and almost 17% over the past month — a steady retreat from early-April levels when shorts briefly nudged above 1 million shares during the tariff-driven volatility. Borrow availability remains loose and cost to borrow is negligible at 0.36% annualised. There is no meaningful squeeze dynamic here. The ORTEX short score of 29.6 sits comfortably low, and availability is well above tight territory, meaning the short side is not a primary tension ahead of the print.
Options positioning has shifted noticeably more defensive since mid-April. The put/call ratio climbed from the low 0.40s in late March to near 0.99 this week — well above its 20-day average of 0.78 — though still roughly one standard deviation above the norm rather than at an extreme. That shift coincides with the broader market volatility in April and likely reflects index-level hedging as much as stock-specific concern. On the ownership side, founder Alan McKim trimmed his holding by 211,265 shares in March, and a broad cohort of executives — including both the President/CEO and Co-CEO — sold shares on the same day in mid-March. The net 90-day insider figure remains in positive territory in share terms, but the pattern of March selling at prices around $288-293 means insiders were reducing at levels below where the stock trades today.
The Q1 print is therefore a test of whether the earnings trajectory can validate a multiple that the Street has already re-rated to near its upper range of recent targets.
See the live data behind this article on ORTEX.
Open CLH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
